Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampion for Prolonged Respiratory Symptoms Due to Long COVID
NCT04880161Phase 1Completed
- Sponsor
- Ampio Pharmaceuticals, Inc.
- Start
- Jul 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aspartyl-alanyl-diketopiperazine in post-acute sequelae of SARS-CoV-2 infection (PASC) (2 arms), sponsored by Ampio Pharmaceuticals, Inc. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events at Day 28. Started Jul 2021; status: completed.
02
Drugs
aspartyl-alanyl-diketopiperazine
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT04880161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880161.